References
Bryson HM, Brogden RN. Drugs 45: 589–621,19
Frampton JE, et al. Drugs 44: 889–917,1992
Fassbender M, et al. Clin Infect Dis 16: 646–653,1993
Gentry LO. Clin Infect Dis 14: 285–297, 1992
Wiseman LR, Benfield P. Drugs 45: 295–317,1993
Konishi K, et al. J Antimicrob Chemother 31: 413–420, 1993
Yu KW, et al. Eur J Clin Microbiol Infect Dis 11: 652–659, 1992
Kissling M, Chadbourne U. Respiration 60 (Suppl. 1): 45–54,1993
Marx MA, Fant WK. Drug Intell Clin Pharm 22: 651–658,1988
Quevedo A, et al. J Oto-Rhino-Laryngol Rel Spec 55: 93–96,1993
Mendelman PM, et al. J Pediatr 121: 459–465,1992
Peixoto E, et al. Curr Ther Res 53: 694–706, 1993
Dajani AS, et a. Pediatr Infect Dis J 12: 275–279, 1993
Chibante A, et al. Drug Invest 4: 252–257, 1992
Gatzola-Karaveli M, et al. Pharmatherpeutica 5: 423–438, 1989
Paupe J, et al. Chemotherapy (Basel) 38: 29–32, 1992
Syrogiannopoulos GA, et al. Curr Ther Res 47: 245–251, 1990
Zuck P, et al. J Antimicrob Chemother 26 (Suppl. E): 71–77, 1990
Stevens DL, et al. Diag Microbiol Infect Dis 16: 123–129, 1993
Del Tacca M, et al. Drug Invest 5: 313–319, 1993
St Peter JV, et al. Antimicrob Agents Chemother 36: 126–131, 1992
Borin MT. et al. J Clin Pharmacol 32: 1038–1044,1992
Rights and permissions
About this article
Cite this article
Orally Active Third-Generation Cephalosporins are Worth Considering in Some Indications. Drugs Ther. Perspect 2, 4–7 (1993). https://doi.org/10.2165/00042310-199302070-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199302070-00002